Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV–hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study

Camma C. , Bruno S. , Di Marco V. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64–71.

Mirandola S. , Realdon S. , Iqbal J. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661–1669.

Okuda M. , Li K. , Beard M.R. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366–375.

Romero-Gomez M. , Del Mar Viloria M. , Andrade R.J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–641.

Conjeevaram H.S. , Kleiner D.E. , Everhart J.E. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80–87.

Sulkowski M.S. , Thomas D.L. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197–207.

Sherman K. , Roustrer S. , Chung R. , Rajicic N. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 2000; 5 Suppl 1: 64–65.

Benhamou Y. , Bochet M. , Di Martino V. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054–1058.

Puoti M. , Bonacini M. , Spinetti A. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134–137.

de Torres M. , Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003; 2: 5–11.

Kramer J.R. , Giordano T.P. , Souchek J. , Richardson P. , Hwang L.Y. , El-Serag H.B. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56–63.

Benhamou Y. , Di Martino V. , Bochet M. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283–287.

Sterling R.K. , Contos M.J. , Sanyal A.J. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 2003; 32: 30–37.

Martin-Carbonero L. , Soriano V. , Valencia E. , Garcia-Samaniego J. , Lopez M. , Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467–1471.

Puoti M. , Spinetti A. , Ghezzi A. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211–217.

Martin-Carbonero L. , Benhamou Y. , Puoti M. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128–133.

Cacoub P. , Geffray L. , Rosenthal E. , Perronne C. , Veyssier P. , Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207–1214.

Bica I. , McGovern B. , Dhar R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492–497.

Selik R.M. , Byers R.H. Jr. , Dworkin M.S. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29: 378–387.

Rosenthal E. , Poiree M. , Pradier C. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803–1809.

Rosenthal E. , Pialoux G. , Bernard N. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14: 183–188.

Chung R.T. , Andersen J. , Volberding P. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451–459.

Torriani F.J. , Rodriguez-Torres M. , Rockstroh J.K. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–450.

Carrat F. , Bani-Sadr F. , Pol S. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839–2848.

Laguno M. , Murillas J. , Blanco J.L. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27–F36.

The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15–20.

Matthews D.R. , Hosker J.P. , Rudenski A.S. , Naylor B.A. , Treacher D.F. , Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

Ozdemir A. , Yalinbas B. , Selamet U. The effect of hepatitis C virus infection on insulin resistance in chronic haemodialysis patients. Yonsei Med J 2007; 48: 274–280.

Masuo K. , Katsuya T. , Ogihara T. , Tuck M.L. Acute hyperinsulinemia reduces plasma leptin levels in insulin-sensitive Japanese men. Am J Hypertens 2005; 18: 235–243.

Manns M.P. , McHutchison J.G. , Gordon S.C. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

Bani-Sadr F. , Goderel I. , Morand P. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART? AIDS 2007; 21: 1645–1648.

Lok A.S. , Everhart J.E. , Chung R.T. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 2007; 5: 245–254.

Dai C.Y. , Huang J.F. , Hsieh M.Y. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712–718.

Harrison S.A. Steatosis and chronic hepatitis C infection: mechanisms and significance. Clin Gastroenterol Hepatol 2005; 3: S92–S96.

Ryan P. , Resino S. , Miralles P. Insulin resistance impairs sustained virologic response to interferon plus ribavirin in HIV/HCV co-infected patients. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract Q-162.

Merchante N. , de los Santos-Gil I. , Merino D. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol 2009; 50: 684–692.

Nasta P. , Gatti F. , Puoti M. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008; 22: 857–861.

Ryan P. , Berenguer J. , Michelaud D. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2009; 50: 109–110.

Bugianesi E. , Marchesini G. , Gentilcore E. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44: 1648–1655.

Chitturi S. , Abeygunasekera S. , Farrell G.C. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373–379.

Moucari R. , Asselah T. , Cazals-Hatem D. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416–423.

Poustchi H. , Negro F. , Hui J. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28–34.

Bani-Sadr F. , Carrat F. , Bedossa P. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20: 525–531.

Mira J.A. , Torre-Cisneros J. , Merino D. Efficacy of pegylated intereron plus ribavirin in HIV/HCV coinfection outside of well circumscribed clinical trials: the Andalusian multicenter study. 13th Conference on Retroviruses and Opportunistic Infections, 5–8 February 2006, Denver, CO, USA. Abstract 861.

D'Souza R. , Sabin C.A. , Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509–1515.

Camma C. , Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50: 648–651.

Shire N. , Rao M. , Andersen J. Improving non-invasive discrimination of fibrosis in HIV/HCV-co-infected patients. 14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 914.

Overbeck K. , Genne D. , Golay A. , Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008; 49: 295–298.

Basu R. , Shah P. , Basu A. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 2008; 57: 24–31.

Shaw R.J. , Lamia K.A. , Vasquez D. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642–1646.

Elgouhari H.M. , Cesario K. , Lopez R. , Zein N. Pioglitazone improves early virologic kinectic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive patients. Hepatology 2008; 48: 383A.

Romero Gomez M. , Diago M. , Andrade R. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naive genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial. Hepatology 2008; 48: 380A.